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ABSTRACT 
The transmissible venereal tumor (TVT) is a contagious neoplasm of round cells that frequently affect dogs. 
The treatment consists of chemotherapy being more effective the vincristine alone, however the resistance 
emergence to this agent due multidrug resistance of the P-glycoprotein (P-gp), a transporter protein encoded 
by the MDR1 gene, has been taking the association with other drugs. Recent studies demonstrated the 
antitumoral effect of the avermectins when associated to the vincristine in the treatment of some neoplasms. 
Therefore, the objective of the present study was to compare the effectiveness of standard treatment of TVT 
with vincristine only when compared to combined treatment with vincristine and ivermectin, evaluated 
through number of applications of the two protocols, histopathological and cytological analysis from 50 dogs 
diagnosed with TVT during the period of 2007 to 2010. The combined protocol significant reduced the 
number of applications and cytological and histopathological findings collaborate with the hypothesis that the 
combination of vincristine and ivermectin promotes faster healing than the use of vincristine alone. 
Combination treatment with vincristine and ivermectin could be in the future an excellent therapeutic 
alternative for the treatment of TVT for probably reducing the resistance to vincristine, simultaneously 
reducing the cost of TVT treatment and promoting a faster recovery of the dog.  
Keywords:  transmissible venereal tumor; ivermectin; vincristine; cytology; histopathology. 
 
 
ANÁLISE HISTOPATOLÓGICA E CITOLÓGICA DO TUMOR VENÉREO TRANSMISSÍVEL EM CÃES 
APÓS DOIS PROTOCOLOS DE TRATAMENTO 
 
 
RESUMO 
O tumor venéreo transmissível (TVT) é uma neoplasia contagiosa de células redondas que afeta 
frequentemente cães. O tratamento consiste no uso de antineoplásicos, sendo mais efetiva a vincristina 
somente, porém o aparecimento de resistência a este agente devido à resistência multidrogas da P-
glicoproteína (P-gp), uma transportadora de proteína codificada pelo gene MDR1, tem levado a associação 
com outras drogas. Estudos recentes demonstraram o efeito antitumoral das avermectinas quando 
associadas à vincristina no tratamento de alguns tipos de neoplasias. Portanto, o objetivo do presente 
estudo foi comparar a eficácia do tratamento padrão do tumor venéreo transmissível (TVT) somente com 
vincristina com o tratamento combinado com vincristina e ivermectina, avaliado através do número de 
aplicações dos dois protocolos e das análises citológica e histopatológica de 50 cães diagnosticados com 
TVT durante o período de 2007 a 2010. O protocolo combinado reduziu significativamente o número de 
aplicações e as análises citológicas e histopatológicas colaboram com a hipótese de que a combinação de 
vincristina e ivermectina promove uma cura mais rápida do que o uso somente da vincristina. O tratamento 
combinado com vincristina e ivermectina pode ser no futuro uma excelente alternativa terapêutica para o 
tratamento do TVT por provavelmente reduzir a resistência à vincristina, simultaneamente reduzindo o custo 
do tratamento e promovendo uma recuperação mais rápida do cão.  
Palavras–chave: tumor venéreo transmissível; ivermectina; vincristina; citologia; histopatologia.   
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INTRODUCTION 
The transmissible venereal tumor (TVT) 
is a naturally occurring round cell neoplasm that 
affects dogs in tropical and subtropical countries 
(MACEWEN, 1996). TVT is located mainly in the 
mucosa of the external genitalia of both sexes, but 
there are reports of cases in oral and nasal 
cavities, eyes, skin, tonsils, liver, pharynx, spleen, 
kidneys, brain, ovary, and foreskin, as well as the 
anal and perianal region (ROGERS et al., 1998; 
DAS; DAS, 2000). 
The methods used to treat TVT are 
cryosurgery, radiotherapy, surgical resection and 
antineoplastic chemotherapy that is the protocol of 
choice in routine clinical treatment (NAK et al., 
2005). Antineoplastic treatment may combine two 
or more chemotherapeutic agents (for example, 
vincristine and cyclophosphamide combined with 
methotrexate), or it can involve a single agent as 
vincristine (in which case is most effective or 
doxorubicin) (MACEWEN, 1996; NAK et al., 
2005). However, the extensive use of vincristine in 
recent years resulted in the emergence of TVT 
resistance to the drug in Brazil with more 
applications than described in the literature (on 
average of four to six applications) (SILVA et al., 
2007; GASPAR et al., 2009). Furthermore, some 
TVT may not respond to multiple administrations 
of chemotherapy (HARMELIN et al., 1995). 
It is known that the main factor 
responsible for the emergence of multidrug 
resistance is the P-glycoprotein (P-gp), a 
transporter protein encoded by the MDR1 gene 
that exists in normal tissues (CNS, intestinal cells, 
renal tubular cells and bile canaliculi) and tumor 
tissues. The P-gp is a substrate for various 
molecules, including for the antineoplastic drug 
vincristine (KORYSTOV et al., 2004) and other 
drugs such as vinblastine, doxorubicin, 
avermectins and loperamide (MEALEY et al., 
2003). The mechanism of action of P-gp is not yet 
fully elucidated, but it is known that it is involved in 
the efflux of substances from within the cell, as an 
important drug efflux pump that is expressed on 
the membranes of blood-brain barrier (BBB) for 
example, thus allowing these to be excreted 
rather than absorbed by the body (DOWLING, 
2006). Neurotoxicity is observed in Collies when 
ivermectin is administered in therapeutic dosages, 
due to a mutation in the MDR1 gene (DOWLING, 
2006; MEALEY et al., 2002; HOPPER et al., 
2002).  
Recently, a study showed the antitumor 
effect of ivermectin in the treatment of some 
cancers in rats (DRINYAEV et al., 2004) and 
another study demonstrated the synergistic effect 
of a combination of avermectin and vincristine that 
may increase the antitumor effect of the 
antineoplastic agent and reduce resistance to 
vincristine, which has become increasingly 
common in recent years (KORYSTOV et al., 
2004). Ivermectin, besides abamectin and 
selamectin, inhibits the P-gp dependent drug 
resistance profiles tumors cells and also is a 
potent substrate and inhibitor for P-gp in Caco-2 
cells (POULIOT et al., 1997; DIDIER; LOOR, 
1996; GRIFFIN et al., 2005). 
Another study (ANDRADE et al., 2009) 
found that a combination of vincristine and 
ivermectin was more effective than treatment with 
vincristine alone, for the treatment of TVT. They 
reported that the former protocol required a 
decreased number of applications, in spite of not 
being statically significant, with no changes to 
physical or haematological analyses. 
Therefore, this study aimed to verify the 
efficacy of the combination of vincristine and 
ivermectin and compare it with the isolated use of 
vincristine in the treatment of TVT, assessing the 
progress of healing through cytological and 
histopathological analyses of the tumor. 
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MATERIAL AND METHODS  
Experimental design 
Fifty dogs from the routine care of a 
Veterinary Teaching Hospital, during august of 
2007 to march of 2010, received clinical, 
cytological and histopathological diagnosis of 
genital TVT. The animals were evaluated by 
physical examination, white and red blood count, 
cytology and biopsy of the tumor before 
administration(s) of the chemotherapeutic(s), 
weekly directly prior to treatment. Information on 
whether the clinician and pathologist evaluating 
was blinded to the treatment group. The samples 
were sent to the Laboratory of Pathological 
Anatomy and read by one and always the same 
pathologist. The number of administrations was 
determined by macroscopic evidence of tumor 
regression, mimicking what is routinely performed 
for treatment of TVT (MACEWEN, 1996; DAS; 
DAS, 2000). The treatment was suspended 
temporarily when the white blood cell count was 
below 3.000/mm3 or platelets were below 
50.000/mm3 or also if the dog exhibited clinical 
signs of vomiting or severe diarrhoea (WHITE, 
1991).  
The dogs were divided randomly into 
two groups of 25 animals as follows: vincristine 
group (VG): 25 dogs (11 males and 14 females); 
age: 4.0 ± 2.4 years; weight: 13.7 ± 6.2 kg; with 
intravenous administration (IV) of vincristine 
sulphate (1 mg/mL) at a dose of 0.5 mg/m2 once a 
week; vincristine with ivermectin group (VIG): 25 
dogs (7 males and 18 females); age: 4.9 ± 2.2 
years; weight: 11.8 ± 7.3 kg; with administration of 
the same dose of vincristine and the same 
intervals between doses as the VG group, plus 
administration of ivermectin (1.0 g/100 mL) 
therefore after administration of the antineoplastic 
agent, at a dose of 400 μL/kg subcutaneously, 
also once a week. 
 
 
Cytological analysis 
Cytology was performed by using a 
gynaecological brush, rubbed against the tumor; 
its contents were stained by Panotic (WRIGHT, 
1989). The microscopic analysis of samples was 
based on general criteria for malignancy 
(pleomorphism; anisocitosis; anisokaryosis and 
number of neoplastic cells); nuclear criteria of 
malignancy (multiple and obvious nucleoli, coarse 
chromatin), and cytoplasmic criteria of malignancy 
(basophilia, vacuolation) in 10 microscopic fields, 
considering the following scores: (0) no change, 
(+) slight change, (+ +) moderate change, (+ + +) 
markedly change, evaluated under optical 
microscope in an increase of 400 X (RASKIN; 
MEYER , 2001). 
 
Histopathological analysis 
Histopathological examination was 
performed by removing a fragment of the mass, 
by cutting with scissors under infiltration of local 
anaesthesia (2% lidocaine chloridrate without 
vasoconstrictor). The fragments were fixed in 
formalin solution and 10% buffer (pH 7.0) for 24 to 
48 hours and then washed in running water for 1 
hour. After that, the tumor fragments were 
processed according to routine technique for 
optical microscopy and embedded in paraffin. We 
cut 5 m sections of all the samples, which were 
stained with haematoxylin and eosin (TOLOSA et 
al., 2003). The microscopic analysis of biopsy 
samples of both group (GV) and the group (GVI) 
was based on the verification of malignancy, 
vascular changes and inflammatory infiltrate 
associated with the neoplasm, which was made 
by the average number of blood vessels and 
mitoses  in 10 microscopic fields in increase of 
400X. Were considered as criteria for malignancy 
(neoplastic infiltration in epidermis and dermis, 
regeneration of skin, number of mitosis and 
neoplastic cells), vascular changes 
(neovascularization and neoplastic infiltration) and  
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inflammatory infiltration (focal, multifocal, diffuse, 
lymphocytic, plasmocitic, neutrophilic and 
macrophages), considering the following scores: 
(0) no change, (+) slight change, (+ +) moderate 
change, (+ + +) markedly change;  while the 
number of mitosis were classified by: (+) 1-3 
mitoses; (+ +) 3 to 5 mitoses (+++) and 5 to 10 
mitoses per field in an increase of 400 X (JONES 
et al., 1997). 
 
Statistical analysis 
The mean values of the number of 
administrations of the protocol treatment in VG 
and VIG, from dogs diagnosed with TVT were 
compared and analyzed by Student t- tests. A 
significance level of P < 0.05 was adopted. For 
assessment of microscopic variables, we adopted 
the "neoplastic infiltration in dermis" criterion in 
biopsies samples for independent observations in 
both groups. We used the binomial test for two 
proportions and BioEstat 5.0 statistical software, 
with a significance level of 5%. The sample size 
was sufficient to approximate binomial distribution 
to the normal curve. 
 
RESULTS AND DISCUSSION 
 The number of administrations with VIG 
protocol was significantly reduced (P < 0.05) than 
VG protocol.  In the VG protocol the numbers of 
administrations were 5.5±1.8 (range 4-9) while in 
VIG protocol was 3.2±1.8 (range 2-8). The criteria 
neoplastic infiltration in dermis was significant 
difference in both protocols. The VIG group 
showed earlier a significantly reduced (P < 0.05) 
than VG protocol in histopathological samples. It 
was statically and clinically significant the 
reduction of the number of administrations and the 
earlier reduction of the neoplastic infiltration in 
dermis in the VIG protocol. It probably reduces the 
resistance induction to vincristine, the costs and 
provides a faster recovery of the dog. It isn’t in 
agreement of another similar study (ANDRADE et 
al., 2009) that analyzed the clinical and 
hematological alterations induced by the use of 
the same protocol and the reduction of the 
number of applications was not statically 
significant, probably by the limited number of the 
dogs sample (n=20) of this study.  
The number of cytological samples 
collect was the same of the number of the 
administration protocol (Table 1). The cytological 
study showed varying degrees of cellular 
pleomorphism (Figure1). The malignant 
characteristics evaluated showed that cytoplasmic 
vacuolization and the presence of loose chromatin 
occurred frequently in the majority of samples 
from the dogs in both groups (Table 1). 
Cytological data also revealed that in samples 
related to the latest applications, in some cases, 
neoplastic cells were not present, even when the 
tumor was observed macroscopically and in 
biopsy. Cytological evaluation frequently 
demonstrated abnormal mitotic profiles and large 
amounts of inflammatory cells, as reported in the 
literature (MOZOS et al., 1996; RASKIN; MEYER, 
2001). However, these alterations were seen only 
in the early collections, when the chemotherapy 
was beginning to exert its effect (Figure 1). 
The number of histopathological 
samples collect was not the same of the number 
of the administration protocol due to the collection 
impossibility for there not being more size of 
appropriate mass for this procedure (Table 2). 
Histopathological study of animals that received 
only vincristine showed cellular pleomorphism 
ranging from moderate to market change. There 
was a predominance of neutrophil and leukocyte 
infiltration in the inflammatory profiles of both 
groups (Table 2). Some biopsies of VIG group 
showed proteinaceous material (Figure 2) that 
was not found in biopsies of VG group. The 
proteinaceous material is found in tumours with 
better prognosis (JONES et al., 1997) and this is 
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not found in biopsies of animals treated only with 
vincristine. 
 Another finding in some samples from 
biopsies was the presence of neoplastic cells in 
dermis when there was no in epidermis. 
Evaluation of malignancy characteristics showed 
the presence of cytoplasmic vacuolation in all 
animals, and large quantities of cells with coarse 
chromatin. The vacuoles play an important role in 
malignancy diagnosis, differentiating this condition 
from others such as mast cell tumor, histiocytoma 
and lymphosarcoma (DUNCAN; PRASSE, 1979; 
MEINKOTH; COWELL, 2002). The presence of 
numerous cells with coarse chromatin indicates a 
high rate of cell proliferation; this variation was 
observed until the last application of 
chemotherapy. 
The inflammatory process revealed by 
the histopathological findings was similar to that 
reported in previous studies (DUNCAN; PRASSE, 
1979), including the prevalence of lymphocytes 
and neutrophils in the collected samples. 
Immunohistochemical studies showed that these 
cells are largely composed of T cells, which are 
important in spontaneous regression of the TVT 
(MOZOS et al., 1996).  
The absence of neoplastic cells in 
cytology in the latest episodes of treatment in 
some dogs, even in the presence on biopsy, may 
be indicative that the cytology exfoliative is 
inefficient as control of the treatment; if tumor 
healing occurs first in the surface, deeper layers 
of the skin would still harbor neoplastic cells. The 
biopsy was more effective for control of the 
treatment, because it draws deeper cells of the 
tumor or the skin of the animal. It is thus still 
possible to find tumor cells that may cause new 
tumor growth even after complete remission 
(MEIKOTH; COWELL, 2002). A possible 
alternative would be the collection of material by 
fine-needle aspiration cytology, which involves the 
collection of cells located in deeper tissue. Further 
research should be performed in order to compare 
the two techniques. 
 
CONCLUSION 
The combined protocol reduces the 
number of applications and cytological and 
histopathological findings collaborate with the 
hypothesis that the combination of vincristine and 
ivermectin promotes faster healing than the use of 
vincristine alone. The combined protocol 
represents a potential alternative therapy for 
reducing the resistance to vincristine, 
simultaneously reducing the cost of TVT treatment 
and a faster recovery of the dog.  
The presence of neoplastic cells in 
dermis when they are absent from epidermis 
demonstrates the importance of histological 
monitoring during TVT treatment. When treatment 
is performed using only the macroscopic aspect or 
exfoliative cytology as a parameter for the 
interruption of treatment, tumor relapses is 
possible.  
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Table 1. Median and percentiles of the cytological analysis of samples taken from 50 dogs diagnosed with 
TVT and treated with vincristine (VG) and vincristine plus ivermectin (VIG). 
 
Criteria of 
Malignancy 
 Samples Collect*/Number of Animals 
 
 
VG Group VIG Group 
 
General 
Criteria 
10/ 
25 
20/ 
25 
30/ 
25 
40/ 
25 
50/ 
15 
60/ 
7 
70/ 
4 
80/ 
4 
90/ 
4 
10/ 
25 
20/ 
25 
30/ 
10 
40/ 
7 
50/ 
3 
60/ 
2 
70/ 
2 
80/ 
1 
Pleomorphi
sm 
2± 
2;3 
2± 
2;3 
1± 
1;2 
0± 
0;2 
1± 
0;1 
1± 
1;1 
1± 
1;1 
0± 
0;0 
0± 
0;0 
2± 
1;3 
1± 
0;3 
1± 
0;3 
0± 
0;3 
0± 
0;2 
2± 
0;2 
1± 
0;1 
0± 
0;0 
Anisocytosi
s 
2± 
2;3 
2± 
2;3 
1± 
1;2 
0± 
0;2 
1± 
0;1 
1± 
0;1 
1± 
1;1 
0± 
0;0 
0± 
0;0 
2± 
1;3 
1± 
0;3 
1± 
0;3 
0± 
0;3 
0± 
0;2 
2± 
0;2 
1± 
0;1 
0± 
0;0 
Anisokaryo
sis 
2± 
2;3 
2± 
2;3 
1± 
1;2 
0± 
0;2 
1± 
0;1 
1± 
0;1 
1± 
1;1 
0± 
0;0 
0± 
0;0 
2± 
1;3 
1± 
0;3 
1± 
0;3 
0± 
0;3 
0± 
0;2 
2± 
0;2 
1± 
0;1 
0± 
0;0 
Number of 
neoplastic 
cells1 
3± 
3;3 
3± 
2;3 
2± 
0;3 
2± 
0;3 
2± 
0;2 
2± 
0;2 
1± 
1;1 
0± 
0;0 
0± 
0;0 
3± 
2;3 
2± 
0;3 
1± 
0;3 
1± 
0;3 
1± 
0;2 
1± 
0;1 
0± 
0;0 
0± 
0;0 
Nuclear 
Criteria 
10/ 
25 
20/ 
25 
30/ 
25 
40/ 
25 
50/ 
15 
60/ 
7 
70/ 
4 
80/ 
4 
90/ 
4 
10/ 
25 
20/ 
25 
30/ 
10 
40/ 
7 
50/ 
3 
60/ 
2 
70/ 
2 
80/ 
1 
Multiple 
and 
obvious 
nucleoli 
3± 
2;3 
2± 
2;3 
2± 
2;3 
0± 
0;3 
3± 
0;3 
3± 
0;3 
2± 
2;2 
0± 
0;0 
0± 
0;0 
3± 
1;3 
2± 
2;3 
1± 
0;3 
0± 
0;3 
0± 
0;2 
1± 
0;1 
1± 
0;1 
0± 
0;0 
Coarse 
chromatin 
3± 
3;3 
2± 
2;3 
2± 
2;3 
0± 
0;3 
2± 
0;2 
2± 
0;2 
1± 
1;1 
0± 
0;0 
0± 
0;0 
3± 
1;3 
2± 
0;3 
1± 
0;3 
0± 
0;3 
0± 
0;3 
0± 
0;0 
0± 
0;0 
0± 
0;0 
Cytoplasma
tic 
Criteria 
10/ 
25 
20/ 
25 
30/ 
25 
40/ 
25 
50/ 
15 
60/ 
7 
70/ 
4 
80/ 
4 
90/ 
4 
10/ 
25 
20/ 
25 
30/ 
10 
40/ 
7 
50/ 
3 
60/ 
2 
70/ 
2 
80/ 
1 
Basophilia 3± 
3;3 
3± 
2;3 
1± 
1;3 
0± 
0;3 
2± 
0;2 
2± 
0;2 
2± 
2;2 
0± 
0;0 
0± 
0;0 
3± 
1;3 
1± 
0;3 
1± 
0;3 
1± 
0;3 
0± 
0;3 
0± 
0;0 
0± 
0;0 
0± 
0;0 
*Cytology sample collect of the tumor before administration(s) of the chemotherapeutic(s), weekly directly prior to treatment. (0) 
Absence of changes; (1) Discrete change; (2) Moderate change; (3) Marked change.  
1Number of neoplastic cells: (0) absent; (1) 10-20 cells per field; (2) 20-40 cells per field; (3) >50 cells per field. 
P < 0.05. 
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Table 2. Median and percentiles of the histopathological analysis of biopsies taken from 50 dogs diagnosed 
with TVT treated with vincristine (VG) and vincristine plus ivermectin (VIG). 
 
Parameters 
Samples Collect*/Number of Animals 
 
VG Group VIG Group 
 
Criteria of 
Malignancy 
10/ 
25 
20/ 
25 
30/ 
25 
40/ 
25 
50/ 
15 
60/ 
7 
70/ 
4 
80/ 
3 
10/ 
25 
20/ 
25 
30/ 
10 
40/ 
7 
50/ 
3 
60/ 
2 
70/ 
2 
Neoplastic 
infiltration 
in 
epidermis1 
1± 
1;3 
1± 
0;1 
1± 
0;1 
1± 
0;2 
1± 
0;1 
1± 
0;1 
1± 
0;1 
0± 
0;0 
2± 
0;3 
1± 
0;2 
0± 
0;1 
0± 
0;1 
0± 
0;0 
0± 
0;0 
0± 
0;0 
Neoplastic 
infiltration 
in dermis1 
3± 
2;3 
3± 
2;3 
2± 
1;3 
1± 
1;3 
3± 
2;3 
3± 
2;3 
3± 
1;3 
2± 
1;2 
3± 
2;3 
2± 
1;3 
2± 
1;3 
2± 
1;3 
2± 
2;2 
2± 
1;2 
1± 
1;1 
Regenera-
tion of 
epidermis2 
0± 
0;1 
1± 
0;2 
2± 
1;3 
3± 
0;3 
0± 
0;3 
3± 
0;3 
3± 
0;3 
3± 
1;3 
0± 
0;3 
2± 
0;3 
2± 
0;3 
3± 
2;3 
3± 
2;3 
3± 
0;0 
3± 
3;3 
Number of 
mitoses  at 
magnificati
on of 400X3 
2± 
1;2 
1± 
0;2 
0± 
0;1 
0± 
0;2 
0± 
0;0 
3± 
0;3 
2± 
0;2 
0± 
0;0 
2± 
1;3 
2± 
0;2 
1± 
0;2 
1± 
0;2 
1± 
1;1 
1± 
1;1 
1± 
0;1 
Vascular 
Changes 
10/ 
25 
20/ 
25 
30/ 
25 
40/ 
25 
50/ 
15 
60/ 
7 
70/ 
4 
80/ 
3 
10/ 
25 
20/ 
25 
30/ 
10 
40/ 
7 
50/ 
3 
60/ 
2 
70/ 
2 
Neovascu-
larization4 
1± 
1;2 
1± 
1;2 
2± 
1;2 
2± 
1;2 
2± 
1;2 
1± 
1;1 
1± 
1;1 
1± 
1;1 
2± 
1;3 
2± 
2;3 
1± 
1;2 
2± 
1;2 
2± 
1;2 
1± 
1;1 
1± 
1;1 
Neoplastic 
infiltration1 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
Inflamma-
tory 
infiltration5 
10/ 
25 
20/ 
25 
30/ 
25 
40/ 
25 
50/ 
15 
60/ 
7 
70/ 
4 
80/ 
3 
10/ 
25 
20/ 
25 
30/ 
10 
40/ 
7 
50/ 
3 
60/ 
2 
70/ 
2 
Focal 
 
0± 
0;0 
0± 
0;1 
0± 
0;2 
0± 
0;2 
1± 
1;1 
1± 
0;1 
1± 
0;1 
1± 
0;1 
0± 
0;1 
0± 
0;1 
0± 
0;2 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
Multifocal 
 
1± 
0;2 
1± 
0;1 
1± 
0;2 
1± 
0;2 
0± 
0;1 
1± 
0;1 
1± 
0;1 
1± 
0;1 
0± 
0;2 
0± 
0;2 
1± 
0;1 
1± 
0;1 
0± 
0;0 
0± 
0;0 
0± 
0;0 
Diffuse 
 
0± 
0;2 
0± 
0;2 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
0± 
0;0 
1± 
0;3 
1± 
0;3 
2± 
0;2 
1± 
0;1 
1± 
1;1 
1± 
1;1 
1± 
0;1 
Lymphocy-
tic 
0± 
0;2 
1± 
0;2 
2± 
1;2 
1± 
0;3 
1± 
1;1 
0± 
0;0 
0± 
0;0 
0± 
0;0 
1± 
0;1 
1± 
0;2 
1± 
0;2 
1± 
1;2 
2± 
2;2 
2± 
1;2 
2± 
0;2 
Plasmocitic 
 
0± 
0;1 
0± 
0;0 
0± 
0;1 
0± 
0;1 
0± 
0;0 
1± 
0;1 
0± 
0;0 
0± 
0;0 
0± 
0;2 
0± 
0;2 
0± 
0;1 
0± 
0;1 
0± 
0;1 
0± 
0;0 
0± 
0;0 
Neutrophilic 
 
2± 
0;3 
1± 
0;2 
1± 
0;1 
0± 
0;1 
0± 
0;0 
3± 
0;3 
0± 
0;0 
0± 
0;0 
2± 
0;3 
1± 
0;2 
1± 
0;3 
0± 
0;1 
0± 
0;0 
0± 
0;0 
0± 
0;0 
Macropha-
ges 
0± 
0;1 
0± 
0;2 
1± 
0;2 
1± 
0;2 
2± 
0;2 
0± 
0;0 
1± 
0;1 
1± 
0;1 
0± 
0;3 
0± 
0;1 
0± 
0;1 
0± 
0;1 
0± 
0;0 
0± 
0;0 
0± 
0;0 
*Biopsy sample collect of the tumor before administration(s) of the chemotherapeutic(s), weekly directly prior to treatment. 1Number of 
neoplastic cells: (0) absent; (1) 10-20 cells per field; (2) 20-40 cells per field; (3) >50 cells per field. 2Regeneration of epidermis: (0) 
without regeneration; (1) only basal layer; (2) basal and prickle cell layer; (3) complete regeneration. 3Number of mitoses: (1) 1-3 
mitoses per field; (2) 3-5 mitoses per field (3) and 5-10 mitoses per field (40 X magnification). 4Neovascularization: (1) 1-3 capillaries per 
field; (2) 3-5 capillaries per field; (3) 5-7 capillaries per field. 5Inflammatory infiltration: (0) absent; (1) ≤20 cells per field; (2) 20-40 cells 
per field; (3) >50 cells per field (40 X magnification). P < 0.05. 
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Figure 1. Cytological analysis of TVT (first collection). A) Large amount of TVT cells (black arrows) and 
inflammatory cells (white arrow) from a VG animal. 40 X magnification. B) Tadpole cell (white arrow) and 
abnormal mitosis (black arrow) in TVT smear from a VIG animal. 100X magnification. 
 
 
 
Figure 2. (A) A cystic formation (arrow) containing the protein material is observed in animal n. 5 Group GVI, 
in the microscopic visualization of 4x, (B) Microscopic view of 10x.  
 
